Page last updated: 2024-09-05

deferasirox and Neoplasms

deferasirox has been researched along with Neoplasms in 7 studies

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (14.29)29.6817
2010's3 (42.86)24.3611
2020's3 (42.86)2.80

Authors

AuthorsStudies
Davidoff, AM; Rankovic, Z; Wang, Y; Wu, Q; Yang, J; Young, B1
Hao, L; Ji, LN; Mao, ZW; Pan, ZY; Rao, LS; Tan, CP; Zhang, H; Zheng, Y1
Alibolandi, M; Babaei, M; Moghadam, SMM; Mosafer, J; Ramezani, M; Saljooghi, AS1
Adamaki, M; Athanasiadou, A; Ktena, YP; Lambrou, G; Moschovi, M1
Bedford, MR; Ford, SJ; Horniblow, RD; Iqbal, TH; Tselepis, C1
Amanlou, M; Arabzadeh, AJ; Ardestani, MS; Delbaz, SA; Ebrahimi, SE; Javidi, A; Mahian, H; Rad, AM1
Ohyashiki, K1

Reviews

3 review(s) available for deferasirox and Neoplasms

ArticleYear
Recent Advances with KDM4 Inhibitors and Potential Applications.
    Journal of medicinal chemistry, 2022, 07-28, Volume: 65, Issue:14

    Topics: Enzyme Inhibitors; Histone Demethylases; Humans; Jumonji Domain-Containing Histone Demethylases; Neoplasms

2022
Iron chelation in the treatment of cancer: a new role for deferasirox?
    Journal of clinical pharmacology, 2013, Volume: 53, Issue:9

    Topics: Animals; Antineoplastic Agents; Benzoates; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Neoplasms; Pyridones; Triazoles

2013
[Development trend in new therapeutic approaches for anemia].
    Nihon rinsho. Japanese journal of clinical medicine, 2008, Volume: 66, Issue:3

    Topics: Anemia; Benzoates; Clinical Trials as Topic; Darbepoetin alfa; Deferasirox; Erythropoietin; Hematinics; Humans; Iron Chelating Agents; Iron Overload; Lenalidomide; Myelodysplastic Syndromes; Neoplasms; Thalidomide; Triazoles

2008

Trials

1 trial(s) available for deferasirox and Neoplasms

ArticleYear
Iron chelation with deferasirox for the treatment of secondary hemosiderosis in pediatric oncology patients: a single-center experience.
    Journal of pediatric hematology/oncology, 2013, Volume: 35, Issue:6

    Topics: Adolescent; Benzoates; Chelation Therapy; Child; Child, Preschool; Deferasirox; Female; Ferritins; Hemosiderosis; Humans; Infant; Iron; Iron Chelating Agents; Male; Neoplasms; Transfusion Reaction; Triazoles; Young Adult

2013

Other Studies

3 other study(ies) available for deferasirox and Neoplasms

ArticleYear
Recoding the Cancer Epigenome by Intervening in Metabolism and Iron Homeostasis with Mitochondria-Targeted Rhenium(I) Complexes.
    Angewandte Chemie (International ed. in English), 2020, 10-12, Volume: 59, Issue:42

    Topics: Animals; Apoptosis; Cell Line, Tumor; Coordination Complexes; Deferasirox; Drug Evaluation, Preclinical; Epigenomics; Histones; Humans; Iron; Iron Chelating Agents; Methylation; Mice; Mitochondria; Neoplasms; Reactive Oxygen Species; Receptors, Antigen, T-Cell; Rhenium; RNA Polymerase II; Signal Transduction

2020
Fabrication of deferasirox-decorated aptamer-targeted superparamagnetic iron oxide nanoparticles (SPION) as a therapeutic and magnetic resonance imaging agent in cancer therapy.
    Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry, 2021, Volume: 26, Issue:1

    Topics: Animals; Antineoplastic Agents; Aptamers, Nucleotide; Cell Line, Tumor; CHO Cells; Contrast Media; Cricetulus; Deferasirox; Female; Humans; Immobilized Nucleic Acids; Iron Chelating Agents; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Magnetite Nanoparticles; Mice, Inbred BALB C; Neoplasms; Precision Medicine; Propylamines; Silanes

2021
Gadolinium-deferasirox-D-glucosamine: novel anti-tumor and MR molecular (theranostic) imaging agent.
    Current radiopharmaceuticals, 2013, Volume: 6, Issue:3

    Topics: Animals; Antineoplastic Agents; Benzoates; Cell Line, Tumor; Chromatography, Thin Layer; Contrast Media; Deferasirox; Disease Models, Animal; Gadolinium; Glucosamine; Glucose; Hexokinase; Humans; Magnetic Resonance Imaging; Mice, Nude; Microscopy, Fluorescence; Neoplasms; Phosphorylation; Radionuclide Imaging; Radiopharmaceuticals; Rats; Time Factors; Triazoles; Tumor Necrosis Factor-alpha

2013